Jean L. Grem
Expertise in
21
conditions

Dr. Jean L. Grem

Oncology
505 S 45th St., 
Omaha, NE 
Accepting New Patients
Offers Telehealth
Expertise in
21
conditions
505 S 45th St., 
Omaha, NE 

Overview

Jean Grem is an Oncologist practicing medicine in Omaha, Nebraska.

Dr. Grem is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, Familial Colorectal Cancer, and Pancreaticoduodenectomy.

She is actively involved in clinical research, co-authoring 43 peer reviewed articles and participating in 11 clinical trials. Dr. Grem is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in NE

Fellowships

University of Wisconsin Hospital, Medical Oncology - 1985
University of Wisconsin Hospital, Medical Oncology - 1986

Hospital Affiliations

St Lukes Regional Medical Center
Bryan Medical Center
Crawford County Memorial Hospital
Bellevue Medical Center
The Nebraska Medical Center

Languages Spoken

English
American Sign Language

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 9 Less Insurance Carriers -

Locations

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center
505 S 45th St., Omaha, NE 68105
Other Locations
Fred & Pamela Buffett Cancer Center - Village Pointe Health Center
111 N. 175th St., Omaha, NE 68118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Phase IIa (Pilot) Study of Neoadjuvant Chemotherapy With Folinic Acid, 5-FU, Irinotecan and Oxaliplatin (FOLFIRINOX) With Digoxin in Patients With Resectable Pancreatic Cancer
A Phase IIa (Pilot) Study of Neoadjuvant Chemotherapy With Folinic Acid, 5-FU, Irinotecan and Oxaliplatin (FOLFIRINOX) With Digoxin in Patients With Resectable Pancreatic Cancer
Enrollment Status: Terminated
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Digoxin, 5Fluorouracil, Calcium Leucovorin, Irinotecan, Oxaliplatin
Study Phase: Phase 2
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Enrollment Status: Completed
Publish Date: June 18, 2025
Intervention Type: Other, Drug
Study Drugs: Clobetasol propionate, Regorafenib
Study Phase: Phase 2
A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors
A Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 with Escalating Doses of Capecitabine Administered Orally to Patients with Advanced, Refractory Gastrointestinal Tract Tumors
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: Eniluracil, Capecitabine
Study Phase: Phase 1
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients
A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients
Enrollment Status: Completed
Publish Date: January 03, 2024
Intervention Type: Genetic, Other, Drug
Study Phase: Phase 1
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors
A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: December 26, 2023
Intervention Type: Drug, Genetic, Other
Study Phase: Phase 1
A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
A Phase II Study of Neo-adjuvant Therapy With Oxaliplatin, Leucovorin, 5-Fluorouracil, Panitumumab (Vectibix) and Radiation in Patients With Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Enrollment Status: Terminated
Publish Date: October 26, 2023
Intervention Type: Biological, Drug, Other, Procedure, Radiation
Study Phase: Phase 2
View 8 Less Clinical Trials

43 Total Publications

The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion.
The circadian gene Dec2 promotes pancreatic cancer progression and dormancy through immune evasion.
Journal: Developmental cell
Published: November 25, 2025
Similar Doctors
Expertise in
42
conditions
Expertise in
42
conditions
Referral may be required

Fred & Pamela Buffett Cancer Center-Nebraska Medical Center

505 S 45th St, 
Omaha, NE 
 (0.1 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicole Shonka is an Oncologist practicing medicine in Omaha, Nebraska. Dr. Shonka is highly rated in 42 conditions, according to our data. Her clinical expertise encompasses Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Shonka is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Fred & Pamela Buffett Cancer Center - Nebraska Medical Center

505 S 45th St., 
Omaha, NE 
 (0.1 miles away)
402-559-5600
Languages Spoken:
English, American Sign Language, French
See accepted insurances
Accepting New Patients

Robert Bociek is an Oncologist practicing medicine in Omaha, Nebraska. Dr. Bociek is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Hodgkin Lymphoma, Bone Marrow Aspiration, and Colonoscopy. Dr. Bociek is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

The Urology Cancer Center

17607 Gold Plz, 
Omaha, NE 
 (11.0 miles away)
402-991-8468
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Luke Nordquist is an Oncologist practicing medicine in Omaha, Nebraska. Dr. Nordquist is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, and Prostatectomy. Dr. Nordquist is currently accepting new patients.

Frequently Asked Questions about Dr. Jean L. Grem

How do I make an appointment with Dr. Jean L. Grem?

You can book an appointment with Dr. Jean L. Grem by calling their office at 402-559-5600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jean L. Grem a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jean L. Grem is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jean L. Grem specialize in?

While Dr. Jean L. Grem is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Neuroendocrine Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jean L. Grem participate in research or clinical trials?

Yes. Dr. Jean L. Grem has published 43 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Jean L. Grem's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jean L. Grem accept my insurance?

Dr. Jean L. Grem accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 402-559-5600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grem's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 12 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile